Cardiovascular

Periprocedural anticoagulation bridging: decision framework

Clinical Overview and When to Suspect Need for Bridging

— Applies almost exclusively to warfarin patients; DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) have short half-lives and do not require bridging

— Bridging is needed only when thromboembolic risk during the warfarin-off window outweighs procedural bleeding risk

— Mechanical heart valve (especially mitral or older-generation aortic)

— Atrial fibrillation with high stroke risk (CHA₂DS₂-VASc ≥ 7, or recent stroke/TIA within 3 months)

— Recent VTE (within 3 months) or severe thrombophilia

— Result: most AF patients on warfarin should NOT be bridged

Step 3 management: Approach every periprocedural anticoagulation question with a 4-step framework: (1) Is the procedure truly high bleeding risk or can anticoagulation continue? (2) What is the agent (warfarin vs DOAC)? (3) What is the thromboembolic risk? (4) Does benefit of bridging exceed bleeding harm?

Definition: Periprocedural anticoagulation bridging = use of a short-acting parenteral anticoagulant (typically LMWH, occasionally UFH) to "cover" the gap when a long-acting oral anticoagulant (warfarin) is held before and after an invasive procedure

Core question on Step 3: "Does this patient need bridging, or can we simply hold the anticoagulant?"

Three indications historically considered for bridging:

Paradigm shift — BRIDGE trial (2015): In AF patients without mechanical valves or recent stroke, no bridging was noninferior to LMWH bridging for arterial thromboembolism and significantly reduced major bleeding (1.3% vs 3.2%)

PERIOP2 trial (2021): Extended this principle — even bileaflet aortic mechanical valves and many AF patients did not benefit from postoperative LMWH bridging

When to suspect bridging is appropriate: mechanical mitral valve, caged-ball valve, mechanical valve + additional risk factor, CHA₂DS₂-VASc ≥ 7, stroke/TIA/systemic embolism < 3 months, VTE < 3 months, severe thrombophilia (protein C/S deficiency, antithrombin deficiency, antiphospholipid syndrome)

Presentation Patterns and Key History

— Indication for anticoagulation: AF (lone vs valvular), mechanical valve (type + position), VTE (provoked vs unprovoked, timing), LV thrombus, antiphospholipid syndrome

— Specific agent and dose: warfarin (target INR range), apixaban 5 mg BID, rivaroxaban 20 mg daily, dabigatran 150 mg BID, edoxaban

— Time since last dose (critical for DOACs)

— Renal function (CrCl) — dictates DOAC clearance timing

— Procedure type and bleeding risk category

— Prior thromboembolic events and timing

— Prior bleeding events on anticoagulation

— Minimal/no hold needed: cataract surgery, dental cleaning/simple extraction, dermatologic biopsy, skin tag removal, joint/soft tissue injection, pacemaker/ICD generator change (BRUISE-CONTROL trial — continue warfarin)

— Low bleeding risk (hold 24 h DOAC, hold warfarin to INR ~1.5): diagnostic endoscopy ± biopsy, GI stent without dilation, simple coronary angiography

— High bleeding risk (hold 48+ h DOAC, full warfarin reversal): major abdominal/cardiothoracic/vascular surgery, neurosurgery, spinal anesthesia, polypectomy of large polyp, ERCP with sphincterotomy, prostate/kidney biopsy, intracranial or spinal procedures

— "Mechanical mitral valve replacement 2003"

— "Stroke 6 weeks ago"

— "DVT 4 weeks ago, started warfarin"

Board pearl: Always note the valve position and generation — mechanical mitral and older (caged-ball, tilting-disc) valves are highest risk. A modern bileaflet aortic mechanical valve without additional risk factors typically does not require bridging.

Typical Step 3 vignette setup: Outpatient on chronic anticoagulation presents to preoperative clinic 1–2 weeks before an elective procedure, OR an inpatient needs an urgent procedure while anticoagulated

Critical history elements to extract:

Procedure bleeding-risk stratification:

Red flag clues that bridging IS indicated:

Physical Exam Findings and Hemodynamic/Bleeding Assessment

— Mechanical valve click (metallic S1 in mitral position, metallic S2 in aortic) — confirms mechanical prosthesis

— Irregularly irregular pulse → AF; assess rate control

— Signs of heart failure (JVD, S3, edema) — affects perioperative risk and renal perfusion → DOAC clearance

— Ecchymoses, petechiae, gingival bleeding, epistaxis history → suggests over-anticoagulation or supratherapeutic INR

— Asymmetric leg swelling → consider active DVT (changes plan dramatically — recent VTE = high thrombotic risk)

— Carotid bruits, prior stroke neurologic deficits — document baseline

— Hypovolemia worsens DOAC accumulation

— Estimate CrCl with Cockcroft-Gault (this is what DOAC labels use, not eGFR)

— Uncontrolled hypertension (>180/110) — defer elective procedure

— Decompensated HF

— Active bleeding from any site

Key distinction: eGFR vs CrCl — DOAC dosing decisions (apixaban dose reduction, dabigatran contraindication at CrCl <30, rivaroxaban dose adjustment) are based on Cockcroft-Gault CrCl, not the MDRD/CKD-EPI eGFR reported on the chemistry panel. Step 3 loves this nuance — using eGFR may lead to incorrect periprocedural hold timing in elderly or low-weight patients.

Pre-procedural exam focus is bleeding-risk and thrombosis-risk surveillance, not diagnosis

Cardiovascular exam:

Vascular and bleeding-tendency exam:

Neurologic baseline: Document focal deficits before any procedure on an anticoagulated patient — protects you medicolegally if postoperative stroke occurs

Volume status and renal perfusion:

Hemodynamic red flags requiring procedure delay:

Functional assessment: METs estimation (≥4 METs without symptoms = adequate functional capacity, lowers perioperative cardiac risk — relevant when combining anticoagulation decisions with overall preop cardiac risk per ACC/AHA 2014 guidelines)

Frailty markers (sarcopenia, unintentional weight loss) — increase bleeding risk and may tip decision toward not bridging

Diagnostic Workup — Initial Labs and Baseline Studies

— CBC — baseline hemoglobin, platelets (heparin/LMWH contraindicated if HIT history; bridging requires platelets >50k generally)

— PT/INR — for warfarin patients; confirms therapeutic range and trends toward goal hold

— aPTT — baseline if UFH bridging planned; also screens for lupus anticoagulant interference

— BMP with creatinine — calculate Cockcroft-Gault CrCl

— LFTs — apixaban and rivaroxaban contraindicated in Child-Pugh C; affects warfarin metabolism

— Type and screen — for high-bleeding-risk procedures

— Check INR 5–7 days before procedure to assess baseline

— Recheck INR day before procedure

— Target INR for procedure day:

▪ <1.5 for most surgeries

▪ <1.2 for neurosurgery/spinal

▪ Continue warfarin (INR 2–3) for cataract, minor dermatologic, pacemaker generator changes

— If INR >1.5 day before surgery: give vitamin K 1–2.5 mg PO

— Routine coagulation tests are NOT reliable for assessing DOAC effect

— Normal PT does NOT exclude rivaroxaban effect; normal aPTT does NOT exclude dabigatran

— Specialized assays exist (anti-Xa calibrated to apixaban/rivaroxaban; dilute thrombin time or ecarin clotting time for dabigatran) — use only in emergencies, bleeding, or unclear timing

CCS pearl: On a CCS case, order INR, CBC, BMP, type & screen in the preop clinic encounter; advance clock to procedure day −1 to recheck INR; document Cockcroft-Gault CrCl in your note to justify DOAC hold duration. The grader rewards explicit periprocedural workflow.

Preprocedural labs for any anticoagulated patient:

Warfarin patients — INR trajectory:

DOAC patients:

ECG: rate/rhythm documentation in AF; QTc baseline if perioperative QT-prolonging drugs anticipated

Imaging: Not routinely required for bridging decisions; consider TTE if mechanical valve dysfunction suspected or LV thrombus needs documentation

Diagnostic Workup — Risk Stratification Tools and Confirmatory Assessment

— CHF (1), HTN (1), Age ≥75 (2), DM (1), Stroke/TIA/TE (2), Vascular disease (1), Age 65–74 (1), Sex female (1)

— High risk for bridging consideration: score ≥7, OR recent stroke/TIA <3 months, OR rheumatic mitral stenosis

— Most AF patients (score 2–6) → no bridging

— High risk → bridge: any mitral mechanical valve; caged-ball or tilting-disc aortic valve; recent (<6 mo) stroke/TIA; mechanical valve + AF + stroke history

— Moderate risk: bileaflet aortic mechanical valve with AF, prior stroke, HTN, DM, CHF, or age >75 → individualize

— Low risk → no bridge: bileaflet aortic mechanical valve without additional risk factors

— High → bridge: VTE <3 months; severe thrombophilia (protein C/S deficiency, antithrombin deficiency, APS, homozygous factor V Leiden, combined defects)

— Moderate: VTE 3–12 months; recurrent VTE; active cancer; heterozygous factor V Leiden/prothrombin → individualize

— Low: single VTE >12 months ago, no other risk factors → no bridge

— HAS-BLED for AF (HTN, abnormal renal/liver, stroke, bleeding, labile INR, elderly, drugs/alcohol)

— Score ≥3 = high bleeding risk; may tip away from bridging

Board pearl: When the question gives you both CHA₂DS₂-VASc score and procedure bleeding risk, work the algorithm: (1) is the procedure high bleeding risk requiring hold? (2) is thromboembolic risk high enough to bridge? Only YES + YES = bridge. Most vignettes are designed so the answer is "hold warfarin, do not bridge."

CHA₂DS₂-VASc (atrial fibrillation thromboembolic risk):

Mechanical valve risk stratification (ACCP/ACC):

VTE risk stratification:

Bleeding risk assessment tools:

Procedure-specific bleeding risk: Use society-specific guidance (ASGE for endoscopy, HRS for cardiac devices, AUA for urology)

Decision Framework and First-Line Management Logic

Step 1 — Is the procedure minor enough to continue anticoagulation?

— Cataract, minor dermatologic, dental cleaning/simple extraction, joint injection, pacemaker generator change → continue warfarin/DOAC

Step 2 — If anticoagulation must be held, what agent?

— DOAC: time-based hold per CrCl and bleeding risk; never bridge a DOAC (short half-life makes bridging unnecessary and harmful)

— Warfarin: proceed to step 3

Step 3 — Stratify thromboembolic risk (warfarin patients only):

— High risk → bridge with LMWH: mechanical mitral valve, older-generation mechanical aortic valve, recent stroke/TIA <3 mo, recent VTE <3 mo, severe thrombophilia, CHA₂DS₂-VASc ≥7 (or per some guidelines ≥6 with prior stroke)

— Low/moderate risk → no bridge: most AF, bileaflet aortic mechanical valve without risk factors, remote VTE

Step 4 — Stratify procedural bleeding risk:

— High bleeding risk + high thrombotic risk → bridge with caution, delay postop LMWH 48–72 h

— Low bleeding risk + high thrombotic risk → bridge per protocol

— Apixaban/rivaroxaban/edoxaban: hold 24 h (low bleeding risk), 48 h (high bleeding risk)

— Dabigatran: CrCl ≥50 → 24/48 h; CrCl 30–49 → 48/72 h; CrCl <30 → avoid or 96 h

Step 3 management: The single most common Step 3 trap is bridging an AF patient with CHA₂DS₂-VASc 3–5 — the correct answer is to hold warfarin 5 days, no LMWH bridge, restart warfarin postop night. Bridging this group causes more bleeding than it prevents strokes.

The unified bridging decision algorithm:

DOAC hold timing (no bridging):

Warfarin hold timing: stop 5 days before procedure (warfarin half-life ~36–42 h, INR drift to <1.5 by day 5 in most)

Pharmacotherapy — Bridging Regimens and Drug Selection

— 1 mg/kg SC q12h (preferred — more consistent levels) or 1.5 mg/kg SC daily

— Renal dose adjustment: CrCl <30 → 1 mg/kg SC q24h

— Start 3 days before procedure (day -3), once INR drifting below therapeutic

— Last dose: 24 hours before procedure at HALF the daily dose if on q12h regimen (or omit evening dose before AM surgery)

— Indicated when LMWH contraindicated: CrCl <30 (some use cautious enoxaparin), high bleeding risk needing rapid reversal, mechanical valve in pregnancy

— Therapeutic IV infusion targeting aPTT 1.5–2.5× control or anti-Xa 0.3–0.7

— Stop UFH 4–6 hours before procedure; check aPTT immediately preop

— Stop warfarin day -5

— Check INR day -1; if >1.5, give vitamin K 1–2.5 mg PO

— Resume warfarin evening of procedure or POD 1 at usual maintenance dose (no loading)

— Low bleeding risk procedure: resume LMWH 24 h postop

— High bleeding risk procedure: resume LMWH 48–72 h postop, often at prophylactic dose initially, advancing to therapeutic

— Continue LMWH until INR therapeutic for 2 consecutive days

— Low bleeding risk: resume 24 h postop

— High bleeding risk: resume 48–72 h postop

— Prophylactic-dose DOAC bridge during this window is not standard; prophylactic LMWH for VTE prophylaxis is acceptable

Board pearl: The last preop LMWH dose timing (24 h before, half dose) is a frequent test point. Full dose within 12 h of neuraxial anesthesia is contraindicated (risk of spinal hematoma — ASRA guidelines require 24 h after therapeutic LMWH).

Preferred bridging agent: LMWH (enoxaparin or dalteparin) — outpatient subcutaneous, no monitoring needed in most

Enoxaparin therapeutic-dose bridging:

Dalteparin: 100 units/kg SC q12h or 200 units/kg SC daily

UFH bridging (inpatient or special situations):

Warfarin management around procedure:

Postoperative bridging resumption:

DOAC resumption (no bridging):

Procedure-Specific Management and Special Scenarios

— BRUISE-CONTROL trial: continued warfarin (INR ≤3) superior to heparin bridging — bridging caused 4× more pocket hematomas

— Step 3 answer: continue warfarin, do not bridge

— DOACs: most evidence supports holding 24–48 h; uninterrupted DOAC is increasingly used (BRUISE-CONTROL-2)

— Uninterrupted anticoagulation (warfarin or DOAC) is preferred — reduces periprocedural stroke

— VENTURE-AF, RE-CIRCUIT trials support uninterrupted DOAC

— Diagnostic ± biopsy: continue or briefly hold; no bridging

— High-risk polypectomy, ERCP with sphincterotomy, EMR: hold per agent, bridge only if very high thrombotic risk

— Warfarin: INR <1.4

— LMWH therapeutic: hold 24 h before

— LMWH prophylactic: hold 12 h before

— DOACs: hold 72 h (per ASRA 2018)

— Spinal epidural hematoma risk — strict timing

— Warfarin: 4-factor PCC (Kcentra) 25–50 units/kg IV + vitamin K 5–10 mg IV (PCC preferred over FFP — faster, less volume, more effective)

— Dabigatran: idarucizumab 5 g IV

— Apixaban/rivaroxaban: andexanet alfa (high dose if last dose <8 h; low dose if >8 h) OR 4-factor PCC 50 units/kg if andexanet unavailable

— LMWH: protamine partial reversal (~60%)

— UFH: protamine 1 mg per 100 units heparin given in last 2–3 h

CCS pearl: For an emergent intracranial hemorrhage on warfarin, the correct CCS order set is: stop warfarin, vitamin K 10 mg IV, 4-factor PCC weight-based, CT head, neurosurgery consult, ICU admit. Do not order FFP first — it is slower and inferior per AHA 2022 ICH guidelines.

Cardiac device implantation (pacemaker/ICD):

Atrial fibrillation ablation:

GI endoscopy:

Neuraxial anesthesia/spinal procedures:

Urgent/emergent surgery on anticoagulation — reversal:

Special Populations — Elderly and Renal/Hepatic Impairment

— Increased bleeding risk with bridging (BRIDGE trial subgroup) — most should not be bridged unless very high thrombotic risk

— Polypharmacy and falls — reassess overall anticoagulation indication

— Use Cockcroft-Gault CrCl (eGFR overestimates in low-muscle-mass elderly)

— Apixaban dose reduction criteria: age ≥80, weight ≤60 kg, Cr ≥1.5 — any 2 of 3 → 2.5 mg BID

— CrCl 30–50:

▪ Enoxaparin: standard or 1 mg/kg q24h

▪ Dabigatran: hold 48–72 h preop

▪ Rivaroxaban: hold 24–48 h

▪ Apixaban: hold 24–48 h

— CrCl 15–30:

▪ Enoxaparin: 1 mg/kg SC q24h (or use UFH)

▪ Dabigatran: avoid (or hold ≥96 h)

▪ Rivaroxaban: hold 48 h

▪ Apixaban: hold 48 h

— CrCl <15/dialysis:

▪ Warfarin or apixaban (only DOAC with limited dialysis data) — bridge with UFH, not LMWH

▪ LMWH accumulates → bleeding risk

— Child-Pugh A: generally safe for all agents with monitoring

— Child-Pugh B: avoid rivaroxaban; use apixaban or warfarin with caution

— Child-Pugh C: avoid all DOACs; warfarin with careful INR monitoring

— Baseline coagulopathy may obviate need for additional anticoagulation hold but complicates INR interpretation

— Vitamin K reversal less effective in cirrhosis

— Avoid all heparins (UFH and LMWH)

— Bridge with argatroban (hepatic clearance) or bivalirudin (renal-adjusted)

— Fondaparinux acceptable for some indications (cross-reactivity rare)

Key distinction: Dabigatran is the most renally cleared DOAC (~80%) — avoid in CrCl <30. Apixaban is the least renally cleared (~27%) — most forgiving in CKD and the only DOAC with FDA-approved use in ESRD/hemodialysis (though data limited).

Elderly (≥75 years):

Renal impairment:

Hepatic impairment:

HIT history:

Special Populations — Pregnancy and Mechanical Valves

— Warfarin: teratogenic (warfarin embryopathy — nasal hypoplasia, stippled epiphyses) especially weeks 6–12; fetal CNS bleeding risk throughout

— DOACs: contraindicated in pregnancy and lactation — no safety data

— LMWH: drug of choice — does not cross placenta, safe in pregnancy and lactation

— UFH: safe but less convenient

— Option 1: LMWH throughout pregnancy with anti-Xa monitoring (target 0.8–1.2 four hours post-dose) — preferred by many

— Option 2: LMWH or UFH first trimester (weeks 6–12), then warfarin until ~36 weeks, then LMWH/UFH to delivery

— Option 3: Warfarin throughout if daily dose ≤5 mg (lowest fetal risk) — controversial

— Switch to IV UFH approaching delivery; stop 4–6 h before delivery

— Treat with therapeutic LMWH (enoxaparin 1 mg/kg SC q12h) throughout pregnancy and 6 weeks postpartum (minimum 3 months total)

— Switch to UFH or hold LMWH 24 h before planned delivery

— Neuraxial anesthesia requires 24 h since last therapeutic LMWH dose

— Resume anticoagulation 6–12 h after vaginal delivery, 12–24 h after C-section

— Warfarin and LMWH both safe in breastfeeding; DOACs are not recommended

— Mechanical valves rare; enoxaparin weight-based with anti-Xa monitoring (target 0.5–1.0)

— Bridging decisions individualized with pediatric hematology

Board pearl: A pregnant woman with a mechanical mitral valve needing cesarean section — the correct sequence is stop LMWH 24 h preop, switch to IV UFH, stop UFH 4–6 h before delivery, resume UFH 6–12 h postop, transition back to warfarin postpartum.

Pregnancy is the highest-stakes anticoagulation scenario on Step 3 — mechanical valves in pregnant women are uniquely complex

General principles:

Mechanical valve in pregnancy — three accepted regimens (ACC/AHA 2020):

VTE in pregnancy:

Postpartum:

Pediatrics:

Complications and Adverse Outcomes

— Major bleeding ~3% with bridging vs ~1% without (BRIDGE trial)

— Surgical site bleeding, hematoma (cardiac device pocket hematoma especially), GI bleed, intracranial hemorrhage

— Higher with combined antiplatelet + bridging anticoagulation

— Stroke/systemic embolism ~0.4% in AF patients held without bridging

— Mechanical valve thrombosis (catastrophic — mortality 15–40%)

— Recurrent VTE/PE

— Pacemaker pocket hematoma — 4× higher with bridging vs continued warfarin

— Spinal/epidural hematoma — devastating; strictly follow ASRA timing

— Intracranial hemorrhage — highest mortality bleeding complication

— Type II HIT — immune-mediated, IgG against PF4-heparin complex

— Platelet drop >50% from baseline, 5–14 days after heparin exposure (or rapid if recent exposure)

— 4T score for pretest probability

— Paradoxical thrombosis (arterial and venous)

— Stop all heparin; start argatroban or bivalirudin; do not give platelets

— Days 3–10 of warfarin initiation, especially in protein C/S deficiency

— Why bridging with heparin is important when starting warfarin in thrombophilia

— Dabigatran — dyspepsia, GI bleeding

— Rivaroxaban — slightly higher GI bleeding than apixaban

— All — reversal availability concerns in emergencies

— Amiodarone, fluconazole, metronidazole, TMP-SMX, statins → ↑ warfarin effect

— Strong CYP3A4/P-gp inhibitors (ketoconazole, ritonavir) → ↑ DOAC levels

— Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) → ↓ DOAC levels

Key distinction: A platelet drop within hours of heparin exposure suggests rapid-onset HIT (prior heparin exposure within 100 days); a drop at 5–10 days is classic. Either way — stop heparin, start non-heparin anticoagulant immediately, don't wait for confirmatory ELISA/SRA.

Bleeding complications of bridging:

Thromboembolic complications of holding without bridging:

Procedure-specific complications:

HIT (heparin-induced thrombocytopenia):

Warfarin-induced skin necrosis:

DOAC-specific adverse events:

Drug interactions complicating periop period:

When to Escalate Care — Consults and Inpatient Triage

— Severe thrombophilia (protein C/S deficiency, antithrombin deficiency, APS triple-positive)

— Active malignancy with thrombosis requiring complex periop management

— HIT diagnosis or suspected HIT

— Recurrent VTE on anticoagulation (anticoagulation failure)

— Pregnancy with mechanical valve or prior VTE

— Mechanical valve patient requiring complex periop planning

— Recent ACS/PCI within 6 months on dual antiplatelet + anticoagulation (triple therapy management)

— Atrial fibrillation with hemodynamic instability or new HF

— Left atrial appendage closure (Watchman) candidacy for high-bleeding-risk patient

— Neuraxial anesthesia planned in anticoagulated patient

— Recent stroke <6 months (delay elective surgery if possible)

— Mechanical valve

— UFH bridging in CrCl <30 or HIT history requiring argatroban

— Pregnancy with mechanical valve near delivery

— Inability to self-administer LMWH and no caregiver

— Unstable INR despite outpatient management

— Major bleeding on anticoagulation requiring reversal agents

— Mechanical valve thrombosis (consider thrombolysis vs surgery)

— Massive PE with hemodynamic instability while bridging

— Postop intracranial hemorrhage

— Complex drug interactions (HIV protease inhibitors + DOAC)

— Transitioning between anticoagulant classes

— Activate reversal protocol immediately

— Do not delay life-threatening surgery for INR normalization — give PCC + vitamin K and proceed

Step 3 management: A patient on apixaban presenting with acute appendicitis needing urgent appendectomy — order andexanet alfa or 4-factor PCC, type & cross, surgery consult, hold further apixaban, proceed to OR. Do not delay for "DOAC washout" in a true emergency.

Hematology consult indications:

Cardiology consult indications:

Anesthesia preop consult:

Inpatient admission for bridging (rare in modern era):

ICU triage:

Pharmacy consult:

Emergency surgery escalation:

Key Differentials — Same-Category Anticoagulation Decisions

— Continue: cataract, simple dental, joint injection, skin biopsy, pacemaker generator change

— Hold: colonoscopy with polypectomy, dental extraction with bone work, deep dermatologic excision

— Bridge: CHA₂DS₂-VASc ≥7 + recent stroke

— No bridge: CHA₂DS₂-VASc 2–6 without recent stroke (vast majority)

— Bridge: any mitral, older aortic, additional risk factors

— No bridge: bileaflet aortic without risk factors

— Reverse: emergent surgery <24 h, high thrombotic risk patient can't wait

— Hold and wait: semi-urgent surgery 24–48 h out, low-moderate thrombotic risk

— Switch warfarin → DOAC: nonvalvular AF preference, INR instability, dietary issues, drug interactions

— Switch DOAC → warfarin: mechanical valve discovered, severe renal failure, pregnancy, cost

— Mechanical valves: only warfarin is approved (dabigatran failed RE-ALIGN trial — increased thrombosis and bleeding)

— Aspirin: continue for most procedures (especially in secondary prevention post-MI/stroke); hold for neurosurgery, prostate, intraocular posterior chamber

— P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel): hold 5–7 days for most surgery; do not hold within 30 days of bare-metal stent or 6 months of DES unless emergent — risk of stent thrombosis

— Triple therapy (DAPT + anticoagulant) — minimize duration; new guidance favors anticoagulant + single P2Y12 inhibitor (AUGUSTUS trial)

Board pearl: A patient with a DES placed 4 months ago needs an elective hernia repair on apixaban + clopidogrel — defer surgery until ≥6 months post-DES. Stopping clopidogrel earlier risks stent thrombosis; the elective procedure can wait.

Distinguishing scenarios that look similar but require different management:

"Hold vs continue" — minor procedures:

"Bridge vs no bridge" in AF:

"Bridge vs no bridge" in mechanical valves:

"Reverse vs hold" in urgent surgery:

"Warfarin vs DOAC switch decisions:

Antiplatelet vs anticoagulant periop decisions:

Key Differentials — Other Considerations Confounding the Decision

— Recent GI bleed → consider holding anticoagulation longer, evaluating need for endoscopic intervention before resumption

— Workup for source (colonoscopy, EGD, capsule) before resumption

— Investigate before bridging — HIT, ITP, drug-induced, sepsis

— Platelets <50k generally contraindicate therapeutic anticoagulation

— Platelets <30k contraindicate even prophylactic anticoagulation

— Anticoagulation timing post-stroke: "1-3-6-12 rule" — TIA day 1, small stroke day 3, moderate stroke day 6, large stroke day 12 (or 2 weeks) before starting/resuming anticoagulation

— Elective surgery ideally deferred 3–6 months post-stroke

— Cancer-associated VTE prefers LMWH or apixaban/rivaroxaban/edoxaban (CLOT, Hokusai-VTE Cancer, Caravaggio trials)

— GI/GU cancers — apixaban preferred over rivaroxaban (less GI bleeding)

— Brain metastases — anticoagulation individualized

— Triple-positive APS: warfarin only — DOACs failed in TRAPS trial (increased thrombosis)

— Bridging recommended for high-risk APS during warfarin hold

— Warfarin standard; emerging DOAC data

— Generally do not bridge for elective procedures unless very high risk

— Bare-metal stent: DAPT 1 month minimum

— Drug-eluting stent: DAPT 6 months minimum (3 months in select)

— Time elective surgery beyond these windows

Key distinction: APS triple-positive (LA + aCL + anti-β2GPI) patients must be on warfarin — DOACs cause higher thrombosis. This is a frequent Step 3 trap where the test-taker assumes DOAC is "easier" and chooses incorrectly. Warfarin with bridging during procedure holds is correct.

Conditions mimicking or modifying bridging decisions:

Active bleeding source:

New diagnosis of thrombocytopenia:

Recent ischemic stroke:

Active malignancy and VTE:

Antiphospholipid syndrome (APS):

LV thrombus, intracardiac thrombus:

Stent considerations:

Secondary Prevention and Long-Term Anticoagulation Plan

— Restart at usual maintenance dose evening of procedure or POD 1

— Continue overlap with LMWH (if bridging) until INR ≥2 for 2 consecutive days

— Typically 5–10 days to reach therapeutic INR

— Recheck INR at day 3–5, then weekly until stable

— Low bleeding risk: 24 h postop

— High bleeding risk: 48–72 h postop

— No loading dose needed (steady state in 2–3 doses)

— If bridging not used, VTE prophylaxis (enoxaparin 40 mg SC daily or 30 mg q12h) during the gap is acceptable for hospitalized patients

— Periprocedural period is ideal for reviewing ongoing need for anticoagulation

— Reconsider:

▪ AF stroke/bleeding risk balance (CHA₂DS₂-VASc vs HAS-BLED)

▪ Provoked VTE >3 months — can often stop

▪ Unprovoked VTE — indefinite anticoagulation, periodically reassess

▪ Active cancer status — continue until cancer in remission

— Consider switch to apixaban for renal-impaired or elderly patients with better safety profile

— Blood pressure control (<130/80) — reduces both stroke and bleeding risk

— Statin if indicated (vascular disease, diabetes, age criteria)

— Lifestyle: smoking cessation, alcohol moderation (<14 drinks/week men, <7 women), weight management

— Fall prevention (PT/OT eval in elderly) — falls are a leading anticoagulation discontinuation reason

— Consider for AF patients with high bleeding risk who cannot tolerate long-term anticoagulation

— Allows eventual discontinuation of anticoagulation

Step 3 management: At every periprocedural encounter, document a reassessment of anticoagulation indication and dose. For an 82-year-old with AF, weight 55 kg, Cr 1.6 on apixaban 5 mg BID — reduce to 2.5 mg BID (meets ≥2 of 3 criteria: age, weight, Cr).

Post-procedure transition back to chronic anticoagulation:

Warfarin resumption:

DOAC resumption:

Long-term anticoagulation reassessment opportunity:

Adjunctive secondary prevention:

LAA closure (Watchman) as alternative:

Follow-Up, Monitoring Parameters, and Patient Counseling

— Surveillance for bleeding (drain output, hemoglobin trend, surgical site exam)

— VTE prophylaxis if therapeutic anticoagulation delayed

— Renal function recheck (perioperative AKI affects DOAC clearance)

— Daily INR until therapeutic

— Daily platelet count if on LMWH (HIT surveillance, esp. days 5–14)

— Discontinue LMWH when INR ≥2 for 2 consecutive days

— INR weekly until stable, then monthly

— Wound check, suture/staple removal

— Reassess for any bleeding events

— Warfarin: INR every 4 weeks once stable; goal time-in-therapeutic-range (TTR) >70%

— DOACs: annual CBC, BMP, LFTs; assess adherence and bleeding/thrombosis events

— All: annual reassessment of indication, dose, drug interactions, bleeding/falls risk

— Carry medication list and indication card (mechanical valve patients should have a card)

— Sign of bleeding: black stools, hematuria, prolonged bleeding from minor cuts, severe headache, sudden weakness

— Sign of thrombosis: leg swelling/pain, chest pain, dyspnea, focal neuro deficit — call 911

— Drug interactions: review with pharmacist before any new prescription (especially antibiotics — TMP-SMX, fluconazole, metronidazole, ciprofloxacin)

— Dietary: warfarin patients — consistent vitamin K intake (not avoidance)

— Alcohol: limit (<2 drinks/day) — affects warfarin metabolism and bleeding risk

— Fall prevention: home safety assessment in elderly

— Travel: stable INR before long trips; carry medications in original bottles

— Once-daily dosing improves adherence (rivaroxaban, edoxaban)

— Short half-lives mean missed doses leave patient unprotected

Board pearl: A patient on warfarin started on TMP-SMX for UTI — recheck INR in 3–5 days; expect significant rise. Either reduce warfarin dose preemptively (20–30%) or choose nitrofurantoin/cephalexin instead if INR control is a concern.

Postoperative follow-up cadence:

First 48 hours postop:

Day 3–7 (warfarin bridging):

Week 2–4:

Long-term monitoring of chronic anticoagulation:

Patient counseling — key teaching points:

Adherence reinforcement (DOACs especially):

Ethical, Legal, and Patient Safety Considerations

— Patient must understand competing risks: bleeding from bridging vs thromboembolism from no bridging

— Document the specific thromboembolic risk (CHA₂DS₂-VASc, valve type) and procedural bleeding risk discussed

— Shared decision-making framework — especially in moderate-risk situations where evidence is uncertain

— In mechanical valve patients, document understanding of valve thrombosis risk and irreversibility of mechanical prosthesis

— Periprocedural anticoagulation is a leading cause of medication errors and adverse events

— Common errors:

▪ Patient not instructed to stop warfarin → INR supratherapeutic at procedure

▪ Patient stops warfarin but is not given bridging instructions

▪ Postoperative anticoagulation not resumed before discharge

▪ DOAC held too long or restarted too early

▪ Communication gaps between surgeon, primary care, anticoagulation clinic

— Use structured protocols, written instructions, and a single accountable clinician (typically the anticoagulation clinic or primary care)

— Medication reconciliation at every transition (admit, transfer, discharge)

— Significant bleeding events or thromboembolic events from anticoagulation errors → root cause analysis

— Hospital-acquired conditions (DVT/PE postop with omitted prophylaxis) may be non-reimbursable under CMS

— Dedicated anticoagulation management services reduce errors by ~50%

— Computerized order sets for bridging reduce variability

— A patient with capacity may refuse anticoagulation — document understanding of stroke/VTE risk

— In mechanical valve patient, refusal of bridging carries high mortality — consider ethics consult

— Affects emergency reversal options (FFP, PCC contain blood-derived products; some accept PCC; vitamin K and andexanet are acceptable)

— Pre-procedural documentation essential

Step 3 management: When a patient is discharged after bridging, the single highest-risk handoff is ensuring INR follow-up. Document: (1) last LMWH dose, (2) warfarin restart date, (3) next INR check date and location, (4) named clinician responsible. This is a frequent UWorld/USMLE Step 3 patient safety vignette.

Informed consent for bridging decisions:

Transition-of-care risk (highest Step 3 yield safety issue):

Mandatory reporting and adverse event disclosure:

Anticoagulation clinics and systems-level safety:

Capacity and refusal:

Jehovah's Witness / blood refusal:

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: Memorize the 5-day warfarin stop, INR check day −1, vitamin K if >1.5, last LMWH dose 24 h before, INR target <1.5 (or <1.2 neuro) on procedure day sequence — this gets tested every cycle.

BRIDGE trial (2015): No bridging noninferior in AF without mechanical valves; bridging caused 2.5× major bleeding — landmark study

BRUISE-CONTROL trial (2013): Continued warfarin > heparin bridge for pacemaker/ICD — 4× less pocket hematoma

PERIOP2 trial (2021): No bridging noninferior even in many mechanical valve and high-risk AF patients

RE-ALIGN trial: Dabigatran failed in mechanical valves — only warfarin approved

TRAPS trial: Rivaroxaban failed in triple-positive APS — warfarin only

Warfarin half-life: 36–42 h → stop 5 days preop

Apixaban half-life: 12 h → hold 24–48 h

Rivaroxaban half-life: 5–13 h → hold 24–48 h

Dabigatran half-life: 12–17 h (renal-dependent) → hold 24–96 h

Enoxaparin half-life: 4–7 h → last dose 24 h preop

Vitamin K dose: 1–2.5 mg PO if INR >1.5 day before surgery; 5–10 mg IV for urgent reversal

4-factor PCC dose: 25–50 units/kg weight-based (capped at 100 kg)

Idarucizumab dose: 5 g IV (two 2.5 g vials) — dabigatran reversal

Andexanet alfa dose: high or low based on agent, dose, timing

CHA₂DS₂-VASc cutoff for high-risk bridging: ≥7 (some use ≥6 with stroke history)

HAS-BLED ≥3: high bleeding risk

INR <1.5: acceptable for most surgeries; <1.2: neurosurgery/spinal

Mechanical valve thrombosis mortality: 15–40%

Major bleeding rate with LMWH bridging: ~3%

Stroke rate in AF without bridging during 5-day hold: ~0.4%

Cockcroft-Gault, not eGFR, for DOAC dosing

Apixaban dose reduction: 2 of 3: age ≥80, weight ≤60 kg, Cr ≥1.5 → 2.5 mg BID

DAPT after DES: 6 months minimum before elective non-cardiac surgery

DAPT after BMS: 1 month minimum

Board Question Stem Patterns

— 72-year-old man with AF (CHA₂DS₂-VASc 4) on warfarin scheduled for elective inguinal hernia repair. Most appropriate periop plan?

— Answer: Stop warfarin 5 days preop; no LMWH bridge; resume warfarin POD 1

— Distractor: "Enoxaparin 1 mg/kg BID starting day -3"

— 58-year-old with mechanical mitral valve (St. Jude, 2008) on warfarin needs colonoscopy with polypectomy.

— Answer: Stop warfarin day -5, start enoxaparin day -3, last dose 24 h preop, resume LMWH 48–72 h postop, continue until INR ≥2 × 2 days

— 65-year-old on apixaban 5 mg BID for AF needs lap chole. CrCl 70.

— Answer: Hold apixaban 48 h preop (high bleeding risk); resume 48 h postop; no bridging

— Patient on warfarin (INR 2.3) for AF needs ICD generator change.

— Answer: Continue warfarin (BRUISE-CONTROL); confirm INR ≤3

— Patient on warfarin (INR 3.2) with traumatic ICH needs craniotomy.

— Answer: 4-factor PCC + IV vitamin K 10 mg; do not delay surgery; not FFP first

— Pregnant patient at 36 weeks with mechanical mitral valve.

— Answer: Switch to IV UFH; stop 4–6 h before delivery

— Patient with stroke 4 weeks ago needs urgent CABG.

— Answer: Bridge (recent stroke = high thrombotic risk); consider delaying if non-urgent

— Patient with DES 3 months ago on aspirin + clopidogrel + apixaban needs cholecystectomy for biliary colic.

— Answer: Defer elective surgery until 6 months post-DES; if urgent, continue at least aspirin

— Mechanical valve patient with prior HIT needs surgery.

— Answer: Argatroban bridge, not heparin/LMWH

Key distinction: Always identify the agent (warfarin vs DOAC) first — DOACs are never bridged. Then stratify thrombotic and bleeding risk. The vast majority of correctly answered Step 3 questions choose "hold without bridging."

Pattern 1 — The "don't bridge" AF trap:

Pattern 2 — The "do bridge" mechanical mitral valve:

Pattern 3 — DOAC simple hold:

Pattern 4 — Continued warfarin for cardiac device:

Pattern 5 — Emergent reversal:

Pattern 6 — Pregnancy mechanical valve:

Pattern 7 — Recent stroke / VTE:

Pattern 8 — Triple therapy and stent:

Pattern 9 — HIT history:

One-Line Recap

Bridge only the highest-risk warfarin patients (mechanical mitral valve, older mechanical aortic valve, recent <3 month stroke or VTE, severe thrombophilia, CHA₂DS₂-VASc ≥7) — for everyone else, simply hold warfarin 5 days preop without LMWH; never bridge DOACs.

— Warfarin stop sequence: Day -5 stop, day -1 check INR (vit K 1–2.5 mg PO if >1.5), procedure day target INR <1.5 (<1.2 for neuro/spinal), resume POD 0–1, no loading

— LMWH bridge regimen (when indicated): Enoxaparin 1 mg/kg SC q12h starting day -3, last dose 24 h preop at half dose, resume 24 h postop (low bleed risk) or 48–72 h (high bleed risk), continue until INR ≥2 × 2 days

— DOAC hold timing: 24 h (low bleed risk) or 48 h (high bleed risk); 48–96 h for dabigatran if CrCl <50; never bridge; use Cockcroft-Gault not eGFR

— Emergent reversal: Warfarin = 4-factor PCC + IV vitamin K (not FFP first); dabigatran = idarucizumab; apixaban/rivaroxaban = andexanet alfa or PCC

— Continue anticoagulation through: cataract surgery, simple dental procedures, joint injections, pacemaker/ICD generator change (BRUISE-CONTROL), AF ablation (uninterrupted preferred)

— Special populations: pregnancy = LMWH (or UFH near delivery), mechanical valves = warfarin only (no DOACs), triple-positive APS = warfarin only, HIT history = argatroban/bivalirudin

— Safety net: Document the bridging plan, the responsible clinician, and the next INR follow-up date at every transition — this is the highest-yield patient safety point on Step 3

Board pearl: When in doubt on a Step 3 periop anticoagulation question, the most commonly correct answer is "hold warfarin without bridging" — the BRIDGE trial decisively reshaped practice in 2015, and exam writers reflect this paradigm shift.

High-yield recap bullets: